ABSTRACT:
The success of mRNA COVID-19 vaccines has transformed the therapeutic landscape, accelerating the development of mRNA-based treatments across diverse applications. While in vitro transcription (IVT) is a powerful method for mRNA production, its efficiency and the resulting product quality depend heavily on the reaction inputs. The choice of RNA polymerase is critical, as it governs transcription initiation and elongation, directly affecting mRNA yield, purity, integrity, capping efficiency and ultimately manufacturing cost and mRNA translatability, the latter a key determinant in mRNA dosing. There is no single polymerase that performs optimally across all template lengths, sequence complexities, and cap and nucleotide chemistries.
Primrose Bio has developed a broad panel of proprietary RNA polymerases (Prima RNApols™) and optimized them using our advanced ultra high throughput enzyme evolution platform. From this panel, we identified Prima RNApols™ ExTend as our lead enzyme for long template mRNA synthesis. Prima RNApols ExTend consistently outperforms T7 RNA polymerase in key IVT metrics, delivering higher yields, improved RNA integrity, reduced double stranded RNA, and broad compatibility with diverse transcription start sites and cap analogs.